Cannabinoids have been shown to modulate the immune system in vitro and in animal models. A major area of interest is how cannabinoids impact the brain. A whole variety of neuropathies or brain disorders, such as AIDS dementia, Parkinson’s disease, Multiple Sclerosis and Alzheimer’s disease, are associated with a hyperinflammatory response within the brain. Microglia, the resident macrophages of the brain, are the major cell type responsible for the persistent elicitation of pro-inflammatory cytokines (IL-1a, IL-1b, IL-6, TNFa) and other mediators. In vitro experiments have demonstrated that the partial exogenous cannabinoid agonist delta-9-tetrahydrocannabinol (D9-THC) and the potent synthetic exogenous cannabinoid agonist CP55940 down-regulate the robust production of pro-inflammatory cytokines elicited in response to bacterial lipopolysaccharide (LPS) at the mRNA level. These observations suggest that cannabinoids, devoid of psychotropic properties, have the potential to betherapeutic agents. These highly lipophilic compounds can pass through the blood brain barrier and act through specific cannabinoid receptors, cannabinoid receptor 1 (CB1) and cannabinoid receptor 2 (CB2). CB1 and CB2 are expressed in the brain and the periphery, respectively, and may serve as molecular targets for ablating chronic brain inflammation. Electrophoretic mobility shift assays (EMSA) were used to assess the effects of D9-THC and CP55940 on the LPS-induced binding interactions of the universal transcription factor NFkB to its cognate promoter binding site in BV-2 microglial-like cells. EMSA analyses demonstrated that the D9-THC and CP55940 down-regulated LPS-induced NFkB binding in BV-2 cells in a biphasic manner. Furthermore, reporter activity assays determined that D9-THC and CP55940 attenuated LPS-induced, NFkB transcriptional activity in the same biphasic manner. We then determined the specificity in which cannabinoids inhibit NFkB function. Real-Time RT-PCR analysis demonstrated that BV-2 cells did not express CB1 mRNA, but they do express CB2 mRNA when untreated and stimulated with IFN-g or LPS. We performed specificity studies using CB1 and CB2 selective agonists and antagonists with our reporter activity assays. The CB1-selective agonist ACEA did not affect NFkB transcriptional activity but the CB2-selective agonist O-2137 exerted a significant decrease in activity. Furthermore, the CB1 antagonist SR141716A could not reverse the inhibitory effects of CP55490 but those effects were blocked by the CB2 antagonist SR144528. Lastly, we determined the site of action in which cannabinoids inhibit NFkB function by assessing the effects of D9-THC and CP55940 on NFkB’s inhibitor protein IkBa. IkBa retains NFkB in the cytoplasm until stimulus-induced cell activation. Neither cannabinoid compound was able to inhibit the phosphorylation of IkBa, which initiates its degradation. However both cannabinoids inhibited the complete degradation of IkBa. Western immunoblot analysis also demonstrated that comparable levels of endogenous and phosphorylated p65, the transactivation subunit of the NFkB protein (p65/p50), were detected in the nucleus of LPS-stimulated BV-2 cells pre-treated with or without D9-THC. These results suggest that, in addition to inhibiting the proteolytic degradation of IkBa, there is also a mechanism of action in the nucleus that prevents the proper binding and subsequent transcriptional activity of NFkB. Collectively, these results suggest that cannabinoids suppress pro-inflammatory cytokine gene expression at the transcriptional level, but it is likely that there is more than one signal transduction pathway involved in the cannabinoid-mediated inhibition of NFkB function.

Inhibition of fatty acid amide hydrolase (FAAH) or monoacylglycerol lipase (MAGL), the chief degradative enzymes of N-arachidonoyl ethanolamine (anandamide; AEA) and 2-arachidonoylglycerol (2-AG), respectively, elicits no or partial substitution for Δ9-tetrahydrocannabinol (THC) in drug discrimination procedures. However, combined inhibition of both enzymes fully substitutes for THC, as well as produces a full constellation of cannabimimetic effects. Because no published report to date have investigated whether an inhibitor of endocannabinoid hydrolysis will serve as a discriminative stimulus, the purpose of this doctoral dissertation was to investigate whether C57BL/6J mice would learn to discriminate SA-57 (4-[2-(4-Chlorophenyl)ethyl]-1-piperidinecarboxylic acid 2-(methylamino)-2-oxoethyl ester), a dual inhibitor of FAAH and MAGL, from vehicle in the drug discrimination paradigm. Also, we sought to determine whether inhibiting both enzymes, or inhibiting one enzyme was necessary to generate the SA-57 discriminative stimulus. Initial experiments showed that SA-57 fully substituted for either CP 55,940 ((-)-cis-3-[2-Hydroxy-4-(1,1-dimethylheptyl)phenyl]-trans-4-(3-hydroxypropyl)cyclohexanol), a high efficacy CB1 receptor agonist in C57BL/6J, mice or AEA in FAAH (-/-) mice. The majority (i.e., 23 of 24) of subjects achieved criteria of discriminating SA-57 (10 mg/kg) from vehicle within 40 sessions, with full generalization occurring 1-2 h post injection. CP 55,940, the dual FAAH-MAGL inhibitor JZL195 (4-nitrophenyl 4-(3-phenoxybenzyl)piperazine-1-carboxylate), the MAGL inhibitors MJN110 (2,5-dioxopyrrolidin-1-yl 4-(bis(4-chlorophenyl)methyl)piperazine-1-carboxylate) and JZL184 (4-[Bis(1,3-benzodioxol-5-yl)hydroxymethyl]-1-piperidinecarboxylic acid 4-nitrophenyl ester) fully substituted for SA-57. Although, the FAAH inhibitors PF-3845 and URB597 did not substitute for SA-57, PF3845 produced a two-fold leftward shift in the MJN110 substitution dose-response curve. In addition, the CB1 receptor antagonist rimonabant blocked the generalization of SA-57 as well as substitution of CP 55,940, JZL195, MJN110, JZL184 for the SA-57 discriminative stimulus. These findings taken together indicate that the inhibition of endocannabinoid-regulating enzymes serve as breaks to prevent overstimulation of CB1 receptors, and MAGL inhibition is the major driving force for generating the SA-57 discriminative stimulus.

Objective: To determine if cannabinoid receptor 2 (CB2) plays a role in atherosclerosis, we investigated the effects of systemic CB2 gene deletion on hyperlipidemia-induced atherogenesis in low density lipoprotein receptor-deficient (Ldlr-/-) mice. Methods and results: Ldlr-/- and CB2/Ldlr double knockout (CB2-/-Ldlr-/-) mice were fed an atherogenic diet for 8 and 12 weeks. Morphometric analysis revealed no significant difference between the atherosclerotic lesion area in the proximal aortas of Ldlr-/- and CB2-/-Ldlr-/- mice after 8 or 12 weeks on the atherogenic diet. The macrophage and smooth muscle cell (SMC) content, as revealed by immunohistochemical staining, did not differ significantly between Ldlr-/- and CB2-/-Ldlr-/- lesions after 8 weeks. However, after 12 weeks, CB2-/-Ldlr-/- lesions displayed greater macrophage content (86.6±4.1 versus 75.2±7.5%, P<0.05) and SMC content (11.1±5.1 versus 4.2±2.4%, P<0.05) compared to controls. Lesional apoptosis, as determined by in situ TUNEL analysis, was reduced ∼50% in CB2-/-Ldlr-/- lesions after 12 weeks. CB2-/-Ldlr-/- lesions displayed significantly reduced collagen content and increased elastin fiber fragmentation after 12 weeks, which was associated with an ∼57% increase in matrix metalloproteinase 9 (MMP) levels. In vitro, CB2-/- macrophages secreted ∼1.8-fold more MMP9 activity than CB2+/+ macrophages. Conclusions: CB2 receptor deficiency affects atherogenesis in Ldlr-null mice by increasing lesional macrophage and SMC content, reducing lesional apoptosis and altering extracellular matrix components, in part, by upregulating MMP9. These results suggest that pharmacological manipulation of CB2 receptors might exert multiple and complex effects on atherogenesis and plaque stability.

Several studies have reported that administration of cannabinoid receptor agonists in inflammatory/autoimmune and CNS injury models resulted in significant attenuation of clinical disease. The beneficial effects correlated with the observed reduction of inflammatory mediators and peripheral immune cell infiltration into the site of inflammation. Previous studies from our laboratories demonstrated that administration of cannabinoid type 2 receptor agonist attenuated disease score and improved recovery in two murine models of neuroinflammation; spinal cord injury (SCI) and experimental autoimmune encephalomyelitis (EAE), a murine model of multiple sclerosis. The goal of the current investigation was to evaluate the mechanisms through which administration of selective cannabinoid-2 receptor (CB2R) agonists modify inflammatory responses and help to improve function in SCI and EAE. In SCI, an acute neuroinflammatory disorder, administration of CB2R agonist at 1 h and 24 h following contusion injury to the cord resulted in improved recovery of motor function and bladder function (the ability to spontaneously void) compared to control animals. Evaluation of inflammatory mediators at 48h demonstrated a dramatic reduction in the expression of the chemokines CXCL9, 10, 11 and cytokines IL-23 and its receptor in CB2R agonist-treated cords. There was also a reduction in the expression of toll-like receptors (TLR1, TLR4, TLR6, and TLR7), which correlated with a decreased number of immunoreactive microglia. Interestingly, at seven days post injury, CB2R agonist-treated injured cords showed a significant reduction in both hematopoietic and myeloid cell infiltration. In EAE, a chronic neuroinflammatory disorder, our laboratories demonstrated previously that administration of a CB2R agonist led to lower disease scores and improved recovery. In this study, we observed reduced numbers of infiltrating hematopoietic and myeloid cells into the spinal cord and brain of CB2 agonist-treated mice. This reduction was observed at the peak of disease (day 17) and the effect was maintained at the chronic stage of disease (day 30). Evaluation of molecules associated with cell migration showed decreased levels of the adhesion molecule VCAM-1 and matrix metalloproteinases MMP-2 and 9 at peak of EAE in treated mice. The decrease in VCAM-1 correlates with our previous observation of decreased leukocyte rolling and adhesion to brain microvasculature. However, the reduction in MMP-2/9 expression suggests that CB2R agonists may also affect leukocyte transmigration into the perivascular space and further infiltration into the CNS parenchyma. This process requires both chemokine cues and the gelatinases MMP2/9. Animals deficient in these MMPs show leukocyte accumulation in the perivascular space and are resistant to EAE. There are no reports in the literature on possible CB2R agonist effects on gelatinases in myeloid cells. Although both MMP-2 and -9 are produced by antigen-presenting cells and act on similar substrates, MMP-9 appears to play a crucial role in EAE. Therefore, we decided to examine the effects of CB2 signaling on MMP-9 expression in myeloid cells, focusing on myeloid bone marrow-derived dendritic cells (BMDC). Activation of bone marrow-derived macrophages, dendritic cells, and primary microglia with the cytokine cocktail TNFα, IL-1ß, IL-6, containing PGE2, which mimicked an inflammatory milieu, resulted in expression of high levels of MMP-9. Treatment with CB2R agonists reduced MMP-9 in all three cell types. Since migration of DC to various sites is required for their activation and for the initiation of adaptive immune responses, we evaluated the effects of CB2R agonists on migration. The reduced levels of MMP-9 correlated with reduced migration of DC to the draining lymph nodes in vivo, as well as reduced migration vitro in the matrigel migration assay. The effect on MMP-9 expression was mediated through CB2R, resulting in reduction in cAMP levels, subsequent decrease in ERK activation, and reduced binding of c-Fos and c-Jun to the AP-1 site in the MMP-9 promoter. We postulate that, by dampening production of MMP-9 and subsequent MMP-9-dependent DC migration, cannabinoids contribute to resolve acute inflammation and to reestablish homeostasis. Selective CB2R agonists might be valuable future therapeutic agents for the treatment of chronic inflammatory conditions by targeting activated immune cells including DC. / Physiology

Activation of the CB1 receptor is modulated by aspartate residue D2.63176 in transmembrane helix (TMH) II. Interestingly, D2.63 does not affect the affinity for ligand binding at the CB1 receptor. Studies in class A GPCRs have suggested an ionic interaction between residues of TMHII and VII. In this report, modeling studies identified residue K373, in the extracellular (EC)-3 loop, in charged interactions with D2.63. We investigated this possibility by performing reciprocal mutations and biochemical studies. D2.63176A, K373A, D2.63176A-K373A, and the reciprocal mutant with the interacting residues juxtaposed, D2.63176K-K373D were characterized using radioligand binding and guanosine 5'-3-O-(thio)triphosphate functional assays. None of the mutations resulted in a significant change in the binding affinity of CP55,940 or SR141716A. Computational results indicate that the D2.63176-K373 ionic interaction strongly influences the conformation(s) of the EC-3 loop, providing a structure-based rationale for the importance of the EC-3 loop to signal transduction in CB1. Specifically, the putative ionic interaction results in the EC-3 loop pulling over the top (extracellular side) of the receptor; this EC-3 loop conformation may serve protective and mechanistic roles. These results suggest that the ionic interaction between D2.63176 and K373 is crucial for CB1 signal transduction. This work may help to aide drug design efforts for the effective treatment of different diseases. The cannabinoid receptors of osteoblasts may represent a target for the treatment of bone disorders such as osteoporosis. Our research demonstrates that cannabinoids can affect important signaling molecules in osteoblasts. In MC3T3-E1 osteoblastic cells, the CB1 antagonist, AM251, has been reported to induce increases in Runx2 mRNA, mineralized bone nodule formation, and activation of signaling molecules such as ERK and AKT (Wu et al., 2011). Studies from our lab characterizing mice in which both CB1 and CB2 receptors were inactivated by homologous recombination have demonstrated increased bone mass coupled with enhanced osteoblast differentiation of bone marrow stromal cells in culture (manuscript in preparation). We explored the effect of antagonizing CB1 and CB2 cannabinoid receptors in osteoblastic cells to gain insights into molecular pathways that may help to explain the effects of the endocannabinoid system (ECS) in bone development. Our data was generated by running time course experiments with MC3T3-E1 cells under the influence of SR141716A, SR144528 or both in combination. The cells were harvested with a lysis buffer at specific time points and analyzed by western blot analysis. Quantification of protein activation was calculated using LiCor imaging equipment and software. Within 15 minutes, treatment with the CB1 receptor antagonist SR141716A resulted in several fold increases in pERK, pSMAD158, and pAKT. SR144528, a CB2 receptor antagonist, caused increases in pERK and pSMAD158, but not pAKT. When both antagonists were applied together, pERK and pSMAD158 levels increased, while pAKT signaling was diminished compared to SR141716A alone. The finding that cannabinoid receptor antagonists alter the activity of the SMAD158 complex is a novel finding, which suggests that cannabinoids can influence bone morphogenic signaling pathways, and therefore play a significant role in osteoblast differentiation and function. / Cell Biology

Modulation of the endocannabinoid system by the administration of exogenous agonists and selective antagonists has been shown to have potential to attenuate the contribution of inflammation to secondary injury in the CNS. The two most well-defined receptors are the CB1 and CB2 receptors. CB2, the cannabinoid receptor expressed primarily on hematopoietic cells and activated microglia, mediates the immunoregulatory functions of cannabinoids. The involvement of CB2 in central nervous inflammation has been demonstrated by using both endogenous and exogenous ligands. We showed previously that CB2 selective agonists inhibited leukocyte rolling and adhesion to CNS microvasculature and ameliorate clinical symptom in both chronic and remitting-relapsing EAE models; and our previous studies also demonstrated therapeutic potential of CB2 agonist improving recovery following spinal cord injury in the mouse. The goal of the current investigation was to evaluate the mechanisms through which administration of a selective cannabinoid-2 (CB2) agonist modifies inflammatory responses and helps to improve function following the injury in central nervous system. In the EAE project, we showed that Gp1a, a highly selective CB2 agonist with a four log higher affinity for CB2 than CB1, reduced clinical scores and facilitated recovery in EAE in conjunction with long term reduction in demyelination and axonal loss. We also established that Gp1a affected EAE through at least two different mechanisms, i.e. an early effect on Th1/Th17 differentiation in peripheral immune organs, and a later effect on the accumulation of pathogenic immune cells in the CNS, associated with reductions in the expression of CNS and T cell chemokine receptors, chemokines and adhesion molecules. This is the first report on the in vivo CB2-mediated Gp1a inhibition of Th17/Th1 differentiation. We also confirmed the Gp1a-induced inhibition of Th17/Th1 differentiation in vitro, both in non-polarizing and polarizing conditions. The CB2-induced inhibition of Th17 differentiation is highly relevant in view of recent studies emphasizing the importance of pathogenic self-reactive Th17 cells in EAE/MS. In spinal cord injury project, we showed that spinal cord injury mice CB2 agonist O-1966 (with affinities to the CB1 and CB2 receptors of 5055±984 and 23±2.1 nM, respectively) had improved motor function, autonomic function. They also had significant reductions in CXCL-9, CXCL-11, dramatic reductions in IL-23p19 expression and its receptor IL-23r, and reduction in the number of immunoreactive microglia. The results reported in this thesis, demonstrated that the combined effect on Th17 differentiation and immune cell accumulation into the CNS, may contribute to the usefulness of CB2 selective ligands as potential therapeutic agents in neuroinflammation. / Physiology

O sistema endocanabinóide (eCB) tem sido reconhecido como um importante modulador da homeostase energética e recentemente estudos o apontam como um possível integrador da homeostase hidroeletrolítica. Estudos recentes do nosso laboratório demonstraram a participação do receptor canabinóide do tipo 1 (CB1R) no controle da secreção neurohipofisária em resposta a expansão hipertônica do volume extracelular. Dessa forma, o presente trabalho visou esclarecer a participação do sistema eCB, particularmente do CB1R, nas respostas neuronais, neuroendócrinas e comportamentais induzidas pela sobrecarga salina de 4 dias (SS). Uma vez que os animais em SS apresentam hipofagia induzida pela hiperosmolalidade, buscou-se avaliar as vias de integração do controle da homeostase energética e do balanço hidroeletrolítico por meio da introdução de um grupo em dieta pareada (pair fed, PF). De forma a investigar a hipótese acima, utilizou-se como ferramenta farmacológica o agonista seletivo CB1R, araquidonil-2-cloroetilamida (ACEA - 0,1g/5L), administrado por via intracerebroventricular (icv). Inicialmente, nosso trabalho mostrou que a SS promoveu aumento da expressão de CB1R tanto nos núcleos supra-óptico (NSO) e paraventricular (NPV) do hipotálamo quanto em estruturas da lâmina terminal [órgão subfornicial (SFO), o órgão vasculoso da lâmina terminal (OVLT) e o núcleo pré-óptico mediano (MnPO)]. Tais observações foram reforçadas pela análise microscópica destas regiões cerebrais por imunofluorescência, que evidenciou aumento da imunomarcação para CB1R no NPV, NSO e SFO em animais submetidos a SS. Estes resultados também mostraram que a maioria dos terminais pré-sinápticos CB1R-positivos estão localizados predominantemente na porção ventral do NSO, na qual predominam neurônios vasopressinérgicos. Os dados mostram ainda que todas as respostas induzidas pela SS foram revertidas após a reintrodução dos líquidos (RL, água e NaCl 0,3M). Já no grupo PF, não foram observadas alterações na expressão de CB1R em nenhuma das áreas avaliadas. No entanto, após a RL, os animais PF apresentaram hipoosmolalidade plasmática e aumento da expressão de CB1R na LT, sendo este último efeito aparentemente mediado por um aumento da expressão deste receptor no SFO. Em animais normoidratados, a administração central de ACEA produziu um aumento significativo na ingestão alimentar, sendo esta resposta ausente nos animais submetidos a SS, apesar do aumento da expressão de CB1R no hipotálamo verificada neste grupo. Entretanto, o pré-tratamento com ACEA foi capaz de potencializar a ingestão de água induzida pela SS, não produzindo efeitos significativos sobre este parâmetro no grupo PF. Este estudo demonstrou ainda que a SS não alterou as concentrações plasmáticas de angiotensina II (ANGII), porém promoveu aumento signficativo nas concentrações plasmáticas de corticosterona, vasopressina (AVP) e ocitocina (OT), além de diminuir a secreção de peptídeo natriurético atrial (ANP). Em animais submetidos a SS, o prétratamento com ACEA potencializou a secreção de corticosterona e preveniu o aumento da secreção de AVP e OT. Por outro lado, não foram observados efeitos da administração de ACEA sobre a secreção de ANP e ANGII induzida pela SS. Após a RL, o grupo SS apresentou normalização das concentrações plasmáticas hormonais, não sendo observados quaisquer efeitos da administração de ACEA nestas condições experimentais. No grupo PF, por sua vez, após a RL foi observada diminuição na secreção de OT e aumento nas concentrações plasmáticas de ANGII, efeitos estes não alterados pelo pré-tratamento com ACEA. Em conjunto, nossos dados sugerem que o CB1R participa ativamente das respostas homeostáticas comportamentais e neuroendócrinas desencadeadas pela SS, sendo estas respostas especificamente relacionadas ao controle da homeostase hidrossalina e não secundárias à hipofagia induzida pela hiperosmolalidade. Desta forma, conclui-se que a participação do CB1R na homeostase hidroeletrolítica ocorre em paralelo e independentemente da modulação exercida por este receptor sobre a homeostase energética. / The endocannabinoid system (eCB) has been recognized as an important modulator of energy homeostasis and recent studies suggest that this system may play a possible integrator role on hydromineral homeostasis. Recent studies from our laboratory demonstrated the involvement of the type 1 cannabinoid receptor (CB1R) in the control of neurohypophyseal secretion in response to hypertonic extracellular volume expansion. Therefore, the present study aimed to clarify the involvement of the ECB system, particularly of CB1Rs, in neuronal, neuroendocrine and behavioral responses induced by 4 days of salt load (SS). Since the animals submitted to SS exhibit a well known state of hyperosmolality-induced hypophagia, we attempted to evaluate the integrated control of energy homeostasis and hydroelectrolytic balance through the introduction of a paired diet group (pair fed, PF). In order to achieve these goals, this study employed as a pharmacological tool the CB1R selective agonist, arachidonoyl-2\'-chloroethylamide (ACEA-0.1g/5L), administered intracerebroventricularly (icv). Initially, our work showed that SS increased the expression of CB1R in both supraoptic (SON) and paraventricular (PVN) nuclei of the hypothalamus, as well as in the structures of the lamina terminalis [subfornical organ (SFO), organum vasculosum of the lamina terminalis (OVLT) and median preoptic nucleus (MnPO)]. These observations were reinforced by the microscopic analysis of these brain regions by immunofluorescence, which showed increased immunostaining for CB1R in the PVN, SON and SFO in animals submitted to SS. These results also showed that most of the presynaptic CB1R-positive terminals are located predominantly in the ventral part of the SON, which is characterized by the presence of vasopressinergic neurons. The data also showed that all SS-induced responses were reversed after reintroduction of fluids (RF, water and 0,3M NaCl). On the other hand, no changes in the expression of CB1R in any of the evaluated areas were observed in the PF group. However, after RF, PF animals showed hypoosmolality and increased expression of CB1R in the LT, being the latter effect apparently mediated by increased expression of this receptor in SFO. In euhydrated animals, the central administration of ACEA produced a significant increase in food intake, being this response absent in animals submitted to SS, despite the increased expression of CB1R in the hypothalamus observed in this group. However, pretreatment with ACEA was able to potentiate SS-induced water intake, producing no significant effect on this parameter in the PF group. This study also demonstrated that SS did not alter plasma concentrations of angiotensin II (ANG II), but significantly increased plasma concentrations of corticosterone, vasopressin (AVP) and oxytocin (OT), and decreased the secretion of atrial natriuretic peptide (ANP). In animals submitted to SS, pretreatment with ACEA enhanced the secretion of corticosterone and prevented the increased secretion of AVP and OT. Moreover, no effect of ACEA was observed on the SS-induced ANG II and ANP secretion. After RF, the SS group showed normalization of hormonal plasma concentrations, and no effects of ACEA administration were verified under these experimental conditions. After RF, the PF group exhibited a decrease in OT secretion and increased plasma concentrations of ANG II, effects that were not altered by pretreatment with ACEA. Taken together, our data suggest that CB1Rs actively participate in behavioral and neuroendocrine homeostatic responses triggered by SS, and that these responses were specifically related to the control of hydromineral homeostasis and not secondary to the hyperosmolality-induced hypophagia. Therefore, we conclude that the involvement of CB1R in electrolyte homeostasis occurs in parallel and independently of the modulation exerted by this receptor on energy homeostasis.

O sistema endocanabinóide (eCB) tem sido reconhecido como um importante modulador da homeostase energética e recentemente estudos o apontam como um possível integrador da homeostase hidroeletrolítica. Estudos recentes do nosso laboratório demonstraram a participação do receptor canabinóide do tipo 1 (CB1R) no controle da secreção neurohipofisária em resposta a expansão hipertônica do volume extracelular. Dessa forma, o presente trabalho visou esclarecer a participação do sistema eCB, particularmente do CB1R, nas respostas neuronais, neuroendócrinas e comportamentais induzidas pela sobrecarga salina de 4 dias (SS). Uma vez que os animais em SS apresentam hipofagia induzida pela hiperosmolalidade, buscou-se avaliar as vias de integração do controle da homeostase energética e do balanço hidroeletrolítico por meio da introdução de um grupo em dieta pareada (pair fed, PF). De forma a investigar a hipótese acima, utilizou-se como ferramenta farmacológica o agonista seletivo CB1R, araquidonil-2-cloroetilamida (ACEA - 0,1g/5L), administrado por via intracerebroventricular (icv). Inicialmente, nosso trabalho mostrou que a SS promoveu aumento da expressão de CB1R tanto nos núcleos supra-óptico (NSO) e paraventricular (NPV) do hipotálamo quanto em estruturas da lâmina terminal [órgão subfornicial (SFO), o órgão vasculoso da lâmina terminal (OVLT) e o núcleo pré-óptico mediano (MnPO)]. Tais observações foram reforçadas pela análise microscópica destas regiões cerebrais por imunofluorescência, que evidenciou aumento da imunomarcação para CB1R no NPV, NSO e SFO em animais submetidos a SS. Estes resultados também mostraram que a maioria dos terminais pré-sinápticos CB1R-positivos estão localizados predominantemente na porção ventral do NSO, na qual predominam neurônios vasopressinérgicos. Os dados mostram ainda que todas as respostas induzidas pela SS foram revertidas após a reintrodução dos líquidos (RL, água e NaCl 0,3M). Já no grupo PF, não foram observadas alterações na expressão de CB1R em nenhuma das áreas avaliadas. No entanto, após a RL, os animais PF apresentaram hipoosmolalidade plasmática e aumento da expressão de CB1R na LT, sendo este último efeito aparentemente mediado por um aumento da expressão deste receptor no SFO. Em animais normoidratados, a administração central de ACEA produziu um aumento significativo na ingestão alimentar, sendo esta resposta ausente nos animais submetidos a SS, apesar do aumento da expressão de CB1R no hipotálamo verificada neste grupo. Entretanto, o pré-tratamento com ACEA foi capaz de potencializar a ingestão de água induzida pela SS, não produzindo efeitos significativos sobre este parâmetro no grupo PF. Este estudo demonstrou ainda que a SS não alterou as concentrações plasmáticas de angiotensina II (ANGII), porém promoveu aumento signficativo nas concentrações plasmáticas de corticosterona, vasopressina (AVP) e ocitocina (OT), além de diminuir a secreção de peptídeo natriurético atrial (ANP). Em animais submetidos a SS, o prétratamento com ACEA potencializou a secreção de corticosterona e preveniu o aumento da secreção de AVP e OT. Por outro lado, não foram observados efeitos da administração de ACEA sobre a secreção de ANP e ANGII induzida pela SS. Após a RL, o grupo SS apresentou normalização das concentrações plasmáticas hormonais, não sendo observados quaisquer efeitos da administração de ACEA nestas condições experimentais. No grupo PF, por sua vez, após a RL foi observada diminuição na secreção de OT e aumento nas concentrações plasmáticas de ANGII, efeitos estes não alterados pelo pré-tratamento com ACEA. Em conjunto, nossos dados sugerem que o CB1R participa ativamente das respostas homeostáticas comportamentais e neuroendócrinas desencadeadas pela SS, sendo estas respostas especificamente relacionadas ao controle da homeostase hidrossalina e não secundárias à hipofagia induzida pela hiperosmolalidade. Desta forma, conclui-se que a participação do CB1R na homeostase hidroeletrolítica ocorre em paralelo e independentemente da modulação exercida por este receptor sobre a homeostase energética. / The endocannabinoid system (eCB) has been recognized as an important modulator of energy homeostasis and recent studies suggest that this system may play a possible integrator role on hydromineral homeostasis. Recent studies from our laboratory demonstrated the involvement of the type 1 cannabinoid receptor (CB1R) in the control of neurohypophyseal secretion in response to hypertonic extracellular volume expansion. Therefore, the present study aimed to clarify the involvement of the ECB system, particularly of CB1Rs, in neuronal, neuroendocrine and behavioral responses induced by 4 days of salt load (SS). Since the animals submitted to SS exhibit a well known state of hyperosmolality-induced hypophagia, we attempted to evaluate the integrated control of energy homeostasis and hydroelectrolytic balance through the introduction of a paired diet group (pair fed, PF). In order to achieve these goals, this study employed as a pharmacological tool the CB1R selective agonist, arachidonoyl-2\'-chloroethylamide (ACEA-0.1g/5L), administered intracerebroventricularly (icv). Initially, our work showed that SS increased the expression of CB1R in both supraoptic (SON) and paraventricular (PVN) nuclei of the hypothalamus, as well as in the structures of the lamina terminalis [subfornical organ (SFO), organum vasculosum of the lamina terminalis (OVLT) and median preoptic nucleus (MnPO)]. These observations were reinforced by the microscopic analysis of these brain regions by immunofluorescence, which showed increased immunostaining for CB1R in the PVN, SON and SFO in animals submitted to SS. These results also showed that most of the presynaptic CB1R-positive terminals are located predominantly in the ventral part of the SON, which is characterized by the presence of vasopressinergic neurons. The data also showed that all SS-induced responses were reversed after reintroduction of fluids (RF, water and 0,3M NaCl). On the other hand, no changes in the expression of CB1R in any of the evaluated areas were observed in the PF group. However, after RF, PF animals showed hypoosmolality and increased expression of CB1R in the LT, being the latter effect apparently mediated by increased expression of this receptor in SFO. In euhydrated animals, the central administration of ACEA produced a significant increase in food intake, being this response absent in animals submitted to SS, despite the increased expression of CB1R in the hypothalamus observed in this group. However, pretreatment with ACEA was able to potentiate SS-induced water intake, producing no significant effect on this parameter in the PF group. This study also demonstrated that SS did not alter plasma concentrations of angiotensin II (ANG II), but significantly increased plasma concentrations of corticosterone, vasopressin (AVP) and oxytocin (OT), and decreased the secretion of atrial natriuretic peptide (ANP). In animals submitted to SS, pretreatment with ACEA enhanced the secretion of corticosterone and prevented the increased secretion of AVP and OT. Moreover, no effect of ACEA was observed on the SS-induced ANG II and ANP secretion. After RF, the SS group showed normalization of hormonal plasma concentrations, and no effects of ACEA administration were verified under these experimental conditions. After RF, the PF group exhibited a decrease in OT secretion and increased plasma concentrations of ANG II, effects that were not altered by pretreatment with ACEA. Taken together, our data suggest that CB1Rs actively participate in behavioral and neuroendocrine homeostatic responses triggered by SS, and that these responses were specifically related to the control of hydromineral homeostasis and not secondary to the hyperosmolality-induced hypophagia. Therefore, we conclude that the involvement of CB1R in electrolyte homeostasis occurs in parallel and independently of the modulation exerted by this receptor on energy homeostasis.

To preserve homeostasis and proper function in every living organism, it is important for cells to communicate with each other and their environment. Cells are constantly processing a huge amount of extracellular stimuli through proteins called receptors. Receptors can transduce the signal from extracellular to intracellular compartments. G- protein coupled receptors are the biggest group, in which also belongs Cannabinoid receptor type 1 (CB1R). Endocannabinoid system regulates many biological processes such as learning, food intake, and movement. Obesity is a serious issue nowadays and in cases of claryfing its molecular-genetic basis, there was found Src homology 3-domain growth factor receptor-bound 2-like (endophilin) interacting protein 1 (SGIP1). SGIP1 has a role in the regulation of energetic balance and its overexpression is leading to a development of obesity. SGIP1 was detected as an interaction partner of CB1R and it had been found that it is involved in internalization via clathrin-mediated endocytosis (CME). Key proteins for initiation and early phase of CME are FCHO1/2, with which SGIP1 shares high sequential homology. However, effect of SGIP1 on internalization of activated CB1R is inhibitory unlike FCHO1/2,wheras detailed mechanism of its function remains unclear. The aim of this...

To preserve homeostasis and proper function in every living organism, it is important for cells to communicate with each other and their environment. Cells are constantly processing a huge amount of extracellular stimuli through proteins called receptors. Receptors can transduce the signal from extracellular to intracellular compartments. G-protein coupled receptors are the biggest group, in which also belongs Cannabinoid receptor type 1 (CB1R). Endocannabinoid system regulates many biological processes such as learning, food intake, and movement. Obesity is a serious issue nowadays and in cases of searching for candidate molecules, there was found Src homology 3-domain growth factor receptor-bound 2-like (endophilin) interacting protein 1 (SGIP1). SGIP1 has a role in the regulation of energetic balance and its overexpression is leading to a development of obesity. SGIP1 was detected as an interaction partner of CB1R and it had been found that it is involved in internalization via clathrin-mediated endocytosis. SGIP1 is very homological with FCHO1/2 - important proteins which participate on early stages of endocytosis. Mechanism of inhibitory effect of SGIP1 on internalization remains unclear. The aim of this study is to clarify the role of distinct domains of SGIP1 in context of endocytosis. Key...